OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CMR57

Chiang Mai Ram Medical Business PCL

Healthcare Facilities & ServicesVerified

Chiang Mai Ram Medical Business PCL maintains a debt-to-equity ratio of 0.9, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 0.37, suggesting potential challenges in meeting short-term obligations. The return on equity of 0.0184 and return on assets of 0.0064 indicate that the company is generating relatively low returns compared to its equity and asset base. The company's profitability is reflected in its net income of 71,803,040 THB, but its operating income of 186,859,330 THB suggests that operational efficiency is a key factor in its financial performance. The gross profit of 373,978,140 THB indicates that the company is managing its production costs effectively. However, the company's returns are below the industry median for healthcare facilities and services, indicating a need for improvement in operational efficiency and cost management. The company's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification reported. This concentration may pose a risk if the pharmaceutical market experiences volatility or regulatory changes. The company's revenue of 1,430,890,730 THB is a key indicator of its market position, but the lack of segment-specific data limits a more detailed analysis. The company's growth trajectory is modest, with a revenue of 1,430,890,730 THB in the latest reporting period. The capital expenditure of -227,366,890 THB indicates a reduction in investment, which may affect long-term growth potential. The free cash flow of 123,229,770 THB suggests that the company has some flexibility in funding operations and investments, but the negative net cash position after subtracting total debt highlights liquidity constraints. The company's risk profile is characterized by medium liquidity risk and low dilution potential. The key risk flag of negative net cash after subtracting total debt indicates that the company may need to secure additional financing to maintain its operations. The dilution potential is low, suggesting that the company is not likely to issue additional shares in the near term. Recent events, including the latest financial filings and transcripts, indicate that the company is maintaining a stable financial position despite the challenges in the healthcare sector. The company's operating cash flow of 745,807,310 THB is a positive sign, but the negative net cash position remains a concern.

30-day price · CMR-0.05 (-3.7%)
Low$1.27High$1.38Close$1.30As of15 May, 00:00 UTC
Profile
CompanyChiang Mai Ram Medical Business PCL
TickerCMR.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Chiang Mai Ram Medical Business PCL operates in the healthcare facilities and services industry, primarily generating revenue through pharmaceuticals and healthcare services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Chiang Mai Ram Medical Business PCL maintains a debt-to-equity ratio of 0.9, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 0.37, suggesting potential challenges in meeting short-term obligations. The return on equity of 0.0184 and return on assets of 0.0064 indicate that the company is generating relatively low returns compared to its equity and asset base. The company's profitability is reflected in its net income of 71,803,040 THB, but its operating income of 186,859,330 THB suggests that operational efficiency is a key factor in its financial performance. The gross profit of 373,978,140 THB indicates that the company is managing its production costs effectively. However, the company's returns are below the industry median for healthcare facilities and services, indicating a need for improvement in operational efficiency and cost management. The company's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification reported. This concentration may pose a risk if the pharmaceutical market experiences volatility or regulatory changes. The company's revenue of 1,430,890,730 THB is a key indicator of its market position, but the lack of segment-specific data limits a more detailed analysis. The company's growth trajectory is modest, with a revenue of 1,430,890,730 THB in the latest reporting period. The capital expenditure of -227,366,890 THB indicates a reduction in investment, which may affect long-term growth potential. The free cash flow of 123,229,770 THB suggests that the company has some flexibility in funding operations and investments, but the negative net cash position after subtracting total debt highlights liquidity constraints. The company's risk profile is characterized by medium liquidity risk and low dilution potential. The key risk flag of negative net cash after subtracting total debt indicates that the company may need to secure additional financing to maintain its operations. The dilution potential is low, suggesting that the company is not likely to issue additional shares in the near term. Recent events, including the latest financial filings and transcripts, indicate that the company is maintaining a stable financial position despite the challenges in the healthcare sector. The company's operating cash flow of 745,807,310 THB is a positive sign, but the negative net cash position remains a concern.
Key takeaways
  • Chiang Mai Ram Medical Business PCL has a moderate debt-to-equity ratio of 0.9, indicating a balanced capital structure.
  • The company's return on equity of 0.0184 and return on assets of 0.0064 suggest that it is generating relatively low returns.
  • The company's liquidity position is characterized as medium, with a current ratio of 0.37, indicating potential challenges in meeting short-term obligations.
  • The company's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification reported.
  • The company's growth trajectory is modest, with a revenue of 1,430,890,730 THB in the latest reporting period.
  • The company's risk profile is characterized by medium liquidity risk and low dilution potential.
  • # RATIONALES
  • {
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$1.43B
Gross profit$374.0M
Operating income$186.9M
Net income$71.8M
R&D
SG&A
D&A
SBC
Operating cash flow$745.8M
CapEx-$227.4M
Free cash flow$123.2M
Total assets$11.25B
Total liabilities$7.34B
Total equity$3.91B
Cash & equivalents$232.6M
Long-term debt$3.54B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$4.19B$528.2M$292.1M-$447.0M
FY-3$5.20B$936.6M$503.9M$467.1M
FY-2$5.07B$618.0M$217.8M$134.8M
FY-1$5.29B$484.3M$130.5M$110.7M
FY0$2.50B$2.66B$2.45B$1.09B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$12.83B$4.16B$720.0k
FY-3$14.19B$5.00B$720.7k
FY-2$12.38B$4.38B$724.4k
FY-1$11.02B$3.77B$270.9M
FY0$8.15B$4.50B$455.1M
PeriodOCFCapExFCFSBC
FY-4$637.7M-$880.3M-$447.0M
FY-3$1.12B-$369.4M$467.1M
FY-2$1.02B-$388.2M$134.8M
FY-1$921.6M-$297.0M$110.7M
FY0$939.7M-$608.2M$1.09B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-6$1.43B$186.9M$71.8M$123.2M
FQ-5$1.25B-$7.8M-$60.5M-$4.3M
FQ-4$1.32B$140.0M$49.2M$85.3M
FQ-3$1.22B$64.7M$24.7M-$282.0M
FQ-2$1.30B$90.1M-$80.0M-$574.9M
FQ0$607.6M$31.8M
PeriodGross %Op %Net %FCF %
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ0
PeriodAssetsEquityCashDebt
FQ-6$11.25B$3.91B$232.6M
FQ-5$11.02B$3.77B$270.9M
FQ-4$10.74B$3.44B$384.3M
FQ-3$10.48B$3.42B$177.8M
FQ-2$10.25B$3.01B$978.0M
FQ0$4.53B$57.5M
PeriodOCFCapExFCFSBC
FQ-6$745.8M-$227.4M$123.2M
FQ-5$921.6M-$297.0M-$4.3M
FQ-4$243.9M-$108.5M$85.3M
FQ-3$394.8M-$238.6M-$282.0M
FQ-2$732.6M-$421.2M-$574.9M
FQ0$41.9M-$25.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.91B
Net cash-$3.31B
Current ratio0.4
Debt/Equity0.9
ROA0.6%
ROE1.8%
Cash conversion10.4%
CapEx/Revenue-15.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricCMRActivity
Op margin13.1%7.7% medp25 -2.4% · p75 15.5%above median
Net margin5.0%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin26.1%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-15.9%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity90.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Last actual EPS-0.00 THB
Last actual revenue1,487,888,400 THB
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-15 00:56 UTC#f756b5f0
Market quoteclose THB 1.30 · shares 4.07B diluted
no public URL
2026-05-15 00:57 UTC#f4bd09b8
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 16:11 UTCJob: e142c859